CSIMarket
 
Agios Pharmaceuticals Inc   (AGIO)
Other Ticker:  
 
 
Price: $29.2900 $-0.65 -2.171%
Day's High: $30 Week Perf: -3.3 %
Day's Low: $ 28.94 30 Day Perf: 9.29 %
Volume (M): 655 52 Wk High: $ 35.50
Volume (M$): $ 19,173 52 Wk Avg: $24.87
Open: $29.88 52 Wk Low: $19.80



 Market Capitalization (Millions $) 1,629
 Shares Outstanding (Millions) 56
 Employees -
 Revenues (TTM) (Millions $) 27
 Net Income (TTM) (Millions $) -352
 Cash Flow (TTM) (Millions $) -51
 Capital Exp. (TTM) (Millions $) 1

Agios Pharmaceuticals Inc
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the development of therapies for cancer and rare genetic diseases. The company utilizes its expertise in cellular metabolism to discover and develop potential treatments. Agios is known for its innovative approaches to targeting specific metabolic pathways that play a critical role in disease progression. The company's pipeline includes both small molecule and antibody-based therapies, with several candidates in various stages of clinical development. Agios Pharmaceuticals aims to deliver breakthrough treatments that can significantly improve the lives of patients in need.


   Company Address: 88 Sidney Street Cambridge 2139 MA
   Company Phone Number: 649-8600   Stock Exchange / Ticker: NASDAQ AGIO
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc's Deficit Widens to $-1.69 Million in Fiscal Year Ending December 31, 2023

Investors are buzzing about Agios Pharmaceuticals Inc after the company recently announced its financial results for the fourth quarter and full year of 2023. Despite posting a shortfall per stock of $-1.69, compared to $0.66 a year before, investors are optimistic about the company's future performance.
The company saw a surge in revenue growth, with a strong increase of 64.803% to $7.10 million from the previous year. Additionally, Agios Pharmaceuticals Inc logged a net shortfall of $-95.940 million for the financial interval closing December 31, 2023, compared to a net income of $36.526 million in the similar quarter a year before.

Clinical Study

Mitapivat's Promising Efficacy in Non-Transfusion-Dependent Thalassemia: A Phase 3 ENERGIZE Study Findings

Published Wed, Jan 3 2024 11:30 AM UTC

The Phase 3 ENERGIZE study has recently analyzed the efficacy and safety of a promising new drug, Mitapivat, in patients with non-transfusion-dependent alpha or beta-thalassemia and released its ground-breaking results. Agios Pharmaceuticals announced the positive news department that the ENERGIZE study of Mitapivat met both its primary and key secondary endpoints, generatin...

Clinical Study

Revolutionizing Sickle Cell Treatment: Agios Reports Amplifying Results in RISE UP Pivotal Study

Published Sun, Dec 10 2023 12:00 AM UTC


Biopharmaceutical company Agios has made a major breakthrough in the treatment of sickle cell disease, it revealed at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. Presenting the positive results garnered from the phase 2 portion of the RISE UP Pivotal study, Agios showcased an innovative approach to combatting a historically stubborn dise...

Clinical Study

Agios' AG-946 Shows Promising Clinical Proof-of-Concept for Anemia Treatment: A Game-Changer for Lower-Risk Myelodysplastic Syndromes

Published Mon, Nov 20 2023 12:00 PM UTC



In a groundbreaking development, Agios Pharmaceuticals has recently announced the successful clinical proof-of-concept in a Phase 2a trial of their novel drug, AG-946, for the treatment of anemia in lower-risk Myelodysplastic Syndromes (MDS). This game-changing advancement not only addresses a significant unmet medical need but also showcases remarkable progress in...

Agios Pharmaceuticals Inc

Agios Pharmaceuticals Fails to Break Even Despite Record Revenue Surge in Q3 2023

Agios Pharmaceuticals Inc, a major player in the pharmaceutical industry, has recently announced some promising developments in its financial results. The company reported that both Mitapivat Dose Arms achieved statistically significant hemoglobin response in the Phase 2 portion of the RISE UP Pivotal Study in Sickle Cell Disease, compared to the placebo arm. This positive data supports the advancement of the study to the Phase 3 portion, which is a significant milestone for the company.
Furthermore, Agios Pharmaceuticals Inc revealed a remarkable revenue improvement of 110.438% year on year, reaching $7.40 million in the fiscal period ending on September 30, 2023. This surge in revenue is commendable, especially considering that many of the company's industry counterparts experienced a contraction in their top-line during the same period. This indicates Agios Pharmaceuticals Inc's resilience and ability to resist the sector's momentum.






 

Agios Pharmaceuticals Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Agios Pharmaceuticals Inc does not provide revenue guidance.

Earnings Outlook
Agios Pharmaceuticals Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com